MIR532: MIR532 is a microRNA that has been found to be significantly up-regulated in a high percentage of hepatocellular carcinoma (HCC) patients who are positive for hepatitis C virus (HCV) [PMC3245605]. No single nucleotide polymorphisms (SNPs) have been identified for MIR532 [PMC6195525]. MIR532 has been used as a normalizer in miRNA expression studies [PMC7266158]. Interestingly, MIR532 has been shown to inhibit the invasiveness of tumor cells, while miR500A, which is located upstream of MIR532, increases tumor invasion [PMC8253104]. MIR532 acts as a tumor suppressor by inhibiting the expression of TERT in ovarian cancer, leading to decreased cell proliferation and lower invasion capacity [PMC8253104]. TERT directly interacts with the upstream region of miR500A but fails to bind the upstream sequence of MIR532, which also contains TBE sequences [PMC8253104]. In ovarian cancer patients, high expression levels of MIR502 and MIR532 have been correlated with overall survival outcome [PMC7359466]. Exosomal MIR532 has also shown prognostic value and is associated with favorable overall survival in acute myeloid leukemia patients [PMC7912829]. The regulation characteristics between the promoters of CLCN5 and MIR532 are distinct, with TTF-1 playing a role in activating the MIR532 promoter but not the CLCN5 promoter [PMC5497805].